Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate.
Mathematical models have been developed to describe nasal epithelial tissue dosimetry with two compounds, vinyl acetate (VA) and methyl methacrylate (MMA), that cause toxicity in these tissues These models couple computational fluid dynamics (CFD) calculations that map airflow patterns within the nose with physiologically based pharmacokinetic (PBPK) models that integrate diffusion, metabolism, and tissue interactions of these compounds. Dose metrics estimated in these models for MMA and VA, respectively, were rates of MMA metabolism per volume of tissue and alterations in pH in target tissues associated with VA hydrolysis and metabolism. In this article, four scientists who have contributed significantly to development of these models describe the many similarities and relatively few differences between the MMA and VA models. Some differences arise naturally because of differences in target tissues, in the calculated measures of tissue dose, and in the modes of action for highly extracted vapors (VA) compared with poorly extracted vapors (MMA). A difference in the approach used to estimate metabolic parameters from human tissues provides insights into interindividual extrapolation and identifies opportunities for studies with human nasal tissues to enhance current risk assessments. In general, the differences in model structure for these two esters were essential for describing the biology of the observed responses and in accounting for the different measures of target tissue dose. This article is intended to serve as a guide for understanding issues of optimum model structure and optimal data sources for these nasal tissue dosimetry models. We also hope that it leads to greater international acceptance of these hybrid CFD/PBPK modeling approaches for improving risk assessment for many nasal toxicants. In general, these models predict either equivalent (VA) or lower (MMA) nasal tissue doses in humans compared with tissue doses at equivalent exposure concentrations in rats.
Andersen
Melvin E
ME
Department of Environmental Health, Colorado State University, Ft. Collins, Colorado, USA. MAnderson@ciit.org
Green
Trevor
T
Frederick
Clay B
CB
Bogdanffy
Matthew S
MS
D000392:Air Movements; D006801:Humans; D019570:Inhalation Exposure; D020366:Methylmethacrylate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008962:Models, Theoretical; D009296:Nasal Cavity / Q000033:anatomy & histology / Q000502:physiology*; D009666:Nose / Q000473:pathology; D018570:Risk Assessment; D013329:Structure-Activity Relationship; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014753:Vinyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*
D014665:Vasodilator Agents; D014753:Vinyl Compounds; D020366:Methylmethacrylate; C011566:vinyl acetate